Skip to content

Study · Not a test of the peptide alone · 2021

2 results

Smart co-delivery of miR-34a and cytotoxic peptides (LTX-315 and melittin) by chitosan based polyelectrolyte nanocarriers for specific cancer cell death induction.

Motiei M, Aboutalebi F, Forouzanfar M, Dormiani K, Nasr-Esfahani MH, Mirahmadi-Zare SZ

Materials science & engineering. C, Materials for biological applications17 Jun 2021Cited by 27 (Europe PMC)

PMID34474818 (opens in a new tab)DOI10.1016/j.msec.2021.112258 (opens in a new tab)PepBankPUB-34474818
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

  1. 01LabNot a test of LTX-315 aloneIn vitro (cells)Mechanism

    In MDA-MB-231 cells, nanocarrier co-delivery of gene and peptides produced synergistic activation of multiple cell death pathways.

    In plain wordsIn cells, nanocarriers delivering gene and peptides produced synergistic activation of multiple cell death pathways.

    Peptide
    LTX-315
    Outcome
    IncreaseMultiple cell death pathways
    Study

    humann: not reported in source

    MDA-MB-231 breast adenocarcinoma cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The spherical nanocarriers with an average size of 123 ± 5 nm and a zeta potential of -36 ± 1 mV demonstrated controlled-release of gene and peptides ensured a synergistic effect in establishing multiple cell death pathways on chemoresistance human breast adenocarcinoma cell line, MDA-MB-231.
    1 context sentence
    Summary · context
    This polyelectrolyte complex has unique physicochemical properties so that the core is considered as an efficient carrier for LTX-315 and melittin peptides, and the shell is suitable for delivery of miR-34a.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

  2. 02LabNot a test of LTX-315 aloneIn vitro (cells)Activity measurement

    In MDA-MB-231 breast adenocarcinoma cells, the study reported an LTX‑315 IC50 of 150 μg/mL after 48 h.

    In plain wordsIn breast cancer cells, the study reported an LTX‑315 IC50 of 150 μg/mL after 48 h.

    Peptide
    LTX-315
    Outcome
    Not applicableCytotoxicity IC50
    Study

    humann: not reported in source

    MDA-MB-231 breast adenocarcinoma cells
    Outcome group
    Tumor growth · Cancer

    Measurements

    IC50
    150 μg/mL
    LTX-315 after 48 h

    Source sentences

    Summary
    an IC50 of 15 μg/mL and 150 μg/mL for melittin and LTX-315, respectively, after 48 h
    1 context sentence
    Summary · context
    This polyelectrolyte complex has unique physicochemical properties so that the core is considered as an efficient carrier for LTX-315 and melittin peptides, and the shell is suitable for delivery of miR-34a.

    In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.